Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Fluidigm Corporation(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the companys management will participate in investor meetings at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021.


GlobeNewswire Inc | Feb 4, 2021 04:02PM EST

February 04, 2021

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the companys management will participate in investor meetings at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021.

Chris Linthwaite, President and CEO, will participate in a virtual fireside chat and present updates regarding Fluidigms business strategy and financial performance at 2:00 pm ET. A live webcast and subsequent replay will be available in the Events & Presentations section of the Fluidigm investor website. The replay will be available two hours after the live session and will be archived for the following 90 days.

About FluidigmFluidigm(Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOFand microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo,Advantaand CyTOF are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. All other trademarks are the sole property of their respective owners.The Advanta Dx SARS-CoV-2 RT-PCR Assay is forIn VitroDiagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. OtherFluidigmproducts are provided for Research Use Only. Not for use in diagnostic procedures.

Available InformationWe use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases,SECfilings, public conference calls, and webcasts.

Contact:

Agnes LeeVice President, Investor RelationsFluidigm Corporation650 416 7423agnes.lee@fluidigm.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC